MTO1
5-taurinomethyluridine-[tRNA] synthase subunit MTO1, mitochondrial
Also known as: MTO1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9Y2Z2
- Gene
- MTO1
- Ensembl
- ENSG00000135297
- Chromosome
- 6
- Canonical length
- 717 aa
- Protein class
- Disease related genes, Human disease related genes, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Cytosol
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene encodes a mitochondrial protein thought to be involved in mitochondrial tRNA modification. The encoded protein may also play a role in the expression of the non-syndromic and aminoglycoside-induced deafness phenotypes associated with a specific mutation in the mitochondrial 12S rRNA gene. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
717 residues, UniProt reviewed canonical sequence.
>Q9Y2Z2|MTO1
1 MFYFRGCGRW VAVSFTKQQF PLARLSSDSA APRTPHFDVI VIGGGHAGTE AATAAARCGS
61 RTLLLTHRVD TIGQMSCNPS FGGIGKGHLM REVDALDGLC SRICDQSGVH YKVLNRRKGP
121 AVWGLRAQID RKLYKQNMQK EILNTPLLTV QEGAVEDLIL TEPEPEHTGK CRVSGVVLVD
181 GSTVYAESVI LTTGTFLRGM IVIGLETHPA GRLGDQPSIG LAQTLEKLGF VVGRLKTGTP
241 PRIAKESINF SILNKHIPDN PSIPFSFTNE TVWIKPEDQL PCYLTHTNPR VDEIVLKNLH
301 LNSHVKETTR GPRYCPSIES KVLRFPNRLH QVWLEPEGMD SDLIYPQGLS MTLPAELQEK
361 MITCIRGLEK AKVIQPDGVL LLLPRMECNG AISAHHNLPL PGYGVQYDYL DPRQITPSLE
421 THLVQRLFFA GQINGTTGYE EAAAQGVIAG INASLRVSRK PPFVVSRTEG YIGVLIDDLT
481 TLGTSEPYRM FTSRVEFRLS LRPDNADSRL TLRGYKDAGC VSQQRYERAC WMKSSLEEGI
541 SVLKSIEFLS SKWKKLIPEA SISTSRSLPV RALDVLKYEE VDMDSLAKAV PEPLKKYTKC
601 RELAERLKIE ATYESVLFHQ LQEIKGVQQD EALQLPKDLD YLTIRDVSLS HEVREKLHFS
661 RPQTIGAASR IPGVTPAAII NLLRFVKTTQ RRQSAMNESS KTDQYLCDAD RLQERELLocalizationUniProt · AlphaFold · HPA
Whether an antibody against MTO1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.26
- Highest tissue expression
- 17 nTPM
Expression across tissuesHPA
Tissue
- liver: 17 nTPM
- kidney: 11 nTPM
- testis: 9.3 nTPM
- tongue: 9 nTPM
- parathyroid gland: 8.7 nTPM
- tonsil: 8.7 nTPM
Single-cell type
- early spermatids: 173 nCPM
- late primary spermatocytes: 110 nCPM
- myonuclei: 68 nCPM
- endometrial luminal cells: 63 nCPM
- neutrophil progenitors: 49 nCPM
- monocyte progenitors: 46 nCPM
Immune cell
- T-reg: 12 nTPM
- MAIT T-cell: 9.2 nTPM
- NK-cell: 8.1 nTPM
- naive CD4 T-cell: 7.9 nTPM
- memory CD4 T-cell: 7.1 nTPM
- total PBMC: 6.9 nTPM
Brain region
- cerebellum: 12 nTPM
- white matter: 10 nTPM
- cerebral cortex: 8.9 nTPM
- pons: 8.2 nTPM
- thalamus: 8.2 nTPM
- basal ganglia: 8.1 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about MTO1.
Disease | AllUniProt
Conditions MTO1 is implicated in, by any mechanism.
- Combined oxidative phosphorylation deficiency 10 (COXPD10) MIM:614702
Disease | GeneticClinVar
70 pathogenic / likely-pathogenic of 828 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Mitochondrial hypertrophic cardiomyopathy with lactic acidosis due to MTO1 deficiency
- Inborn genetic diseases
- Fetal anomalies with a likely genetic cause
- Mitochondrial oxidative phosphorylation disorder
- Abnormal brain morphology
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.64
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.65
- DepMap mean gene effect
- -0.23
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- FAD/NAD(P)-binding domain superfamily
- tRNA uridine 5-carboxymethylaminomethyl modification enzyme MnmG-related
- MnmG-related, conserved site
- tRNA uridine 5-carboxymethylaminomethyl modification enzyme MnmG, C-terminal
- MnmG, N-terminal domain
- tRNA uridine 5-carboxymethylaminomethyl modification enzyme, C-terminal subdomain superfamily
- tRNA uridine 5-carboxymethylaminomethyl modification enzyme, C-terminal subdomain
- tRNA uridine 5-carboxymethylaminomethyl modification enzyme, C-terminal, N-terninal subdomain
- Glucose inhibited division protein A
- tRNA modifying enzyme MnmG/GidA C-terminal helical bundle
- tRNA modifying enzyme MnmG/GidA C-terminal helical domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of MTO1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads MTO1 as an antibody target. Whether an autoantibody or antibody against MTO1 could matter depends on whether native MTO1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
MTO1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label MTO1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...